Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis | Zendy

Rokeya Tasneen | Zendy; Deborah S. Mortensen | Zendy; Paul J. Converse | Zendy; Michael E. Urbanowski | Zendy; Anna M. Upton | Zendy; Nader Fotouhi | Zendy; Eric L. Nuermberger | Zendy; Natalie A. Hawryluk | Zendy

Open Access

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

Author(s) -

Rokeya Tasneen,

Deborah S. Mortensen,

Paul J. Converse,

Michael E. Urbanowski,

Anna M. Upton,

Nader Fotouhi,

Eric L. Nuermberger,

Natalie A. Hawryluk

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00253-21

Subject(s) - pi3k/akt/mtor pathway , mtorc1 , mtorc2 , sirolimus , pharmacology , autophagy , mechanistic target of rapamycin , cancer research , biology , signal transduction , microbiology and biotechnology , apoptosis , biochemistry

Efforts to develop more effective and shorter-course therapies for tuberculosis have included a focus on host-directed therapy (HDT). The goal of HDT is to modulate the host response to infection, thereby improving immune defenses to reduce the duration of antibacterial therapy and/or the amount of lung damage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research